Cell and Gene Manufacturing and Logistics
-
4 Key Autologous Manufacturing Challenges (Plus How To Solve Them)
5/17/2024
The manufacturing process for autologous therapies is complex and highly customized, requiring well-orchestrated transport, careful planning, and tight control of many discrete and manual processing steps.
-
Freezing Studies For Single-Use Solutions
5/17/2024
Learn about the four common types of cryogenic studies for advanced therapies: controlled-rate, long-term, therapy containment/protection, and transportation.
-
Adapting Clinical Supply Strategies Through The Phases
5/17/2024
Phase-appropriate logistics are essential to manage resources efficiently, maintain regulatory compliance, and ensure timely delivery.
-
How To Unlock Efficiency In MES Integrations
5/16/2024
This article outlines the significant benefits and framework for manufacturing execution system (MES) integration with systems such as enterprise resource planning.
-
Virotherapy Manufacturing
5/15/2024
Seamlessly delivering your virotherapy
With industry-leading viral expertise, ReciBioPharm navigates the rapidly evolving field of virotherapy to support the development and manufacturing of your gene therapies, viral vector vaccines and oncolytic viruses (OVs).
-
RNA Therapies
5/15/2024
One Team, One Roof, One CDMO
ReciBioPharm’s expanded biologics services and technologies encompass the entire RNA development and manufacturing value chain, helping to deliver your innovation to patients seamlessly.
-
Biologics Development
5/15/2024
ReciBioPharm offers industry-leading biologics development services to support global clients in all clinical phases and global regulatory arenas. Our comprehensive development services include both process and formulation development.
-
Biologics Manufacturing
5/15/2024
ReciBioPharm GMP manufacturing units focus on process robustness and consistency to ensure product quality, purity and efficacy. Our multi-product manufacturing facilities feature state-of-the-art equipment for animal cell-derived viral and microbial products for your clinical trials in phase 1-2 and in accordance with cGMP guidelines.
-
How Advanced PAT Aids Quality By Digital Design In mRNA Manufacturing
5/15/2024
QbDD is an improvement over the QbD paradigm. Here, computational models are used to characterize, monitor, control, and improve manufacturing processes.
-
Tackling Antimicrobial Resistance
5/14/2024
Learn how three companies collaborated to develop and new antibiotic to address the increasing development of antimicrobial resistance (AMR) that threatens the global health landscape.